Phase II Interstitial Colloidal 32P Integrated in The Treatment of Non-Resectable Pancreatic Cancer
- Determine the response/remission rate, survival, and degree of local control from
interstitial colloidal phosphorus P32 followed by external beam radiotherapy and
chemotherapy in patients with unresectable pancreatic cancer.
OUTLINE: Patients are stratified according to prior therapy (yes vs no).
Patients receive dexamethasone intratumorally, then macroaggregated albumin and interstitial
phosphorus P32 intratumorally. Most patients receive a second course of this brachytherapy.
Patients then proceed to chemoradiotherapy beginning 7-14 days after brachytherapy.
Radiotherapy is administered 5 days a week for 6.4 weeks. Fluorouracil IV is administered
every other day for 4 doses during weeks 1 and 2.
Patients are followed monthly for 1 year then every 3 months thereafter.
PROJECTED ACCRUAL: A total of 48 patients will be accrued for this study.
Primary Purpose: Treatment
Stanley E. Order, MD, ScD, FACR
Center for Molecular Medicine
United States: Federal Government
|Northside Hospital Cancer Center||Atlanta, Georgia 30342-1611|
|Center for Molecular Medicine||Garden City, New York 11530|